Sylvester Comprehensive Cancer Center

  • Alliance A071401 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:

    IRB: 20151026

    		SDG: Neuro Oncology
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Alliance

    Enrolling Sites:

    Deerfield
    Kendall
    Sylvester
    Title:

    A071401: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
    Eligibility Criteria - NCT02523014 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180606 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:

    IRB: 20180606

    		SDG: Neuro Oncology
    Disease Site(s):

    Brain and Nervous System
    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    Title:

    Non-invasive glioma characterization through molecular imaging
    Eligibility Criteria - NCT03684109 *This information has been extracted from " www.clinicaltrials.gov"

  • GCAR-7213 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Yaima de la Fuente
    RCphone +1 (305) 6890976

    IRB: 20190401

    		SDG: Neuro Oncology
    Disease Site(s):

    Brain and Nervous System
    Sponsor: GCAR

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    GBM AGILE MASTER PROTOCOL:GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)
    Eligibility Criteria - NCT03970447 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221037 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:

    IRB: 20221037

    		SDG: Neuro Oncology
    Disease Site(s):

    Multiple
    Sponsor: Fore Biotherapeutics Inc

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
    Eligibility Criteria - NCT05503797 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230388 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:

    IRB: 20230388

    		SDG: Neuro Oncology
    Disease Site(s):

    Brain and Nervous System
    Sponsor: ETCTN

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma
    Eligibility Criteria - NCT05432804 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231209 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:

    IRB: 20231209

    		SDG: Neuro Oncology
    Disease Site(s):

    Brain and Nervous System
    Sponsor: ETCTN

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion
    Eligibility Criteria - NCT05859334 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240880 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:

    IRB: 20240880

    		SDG: Neuro Oncology
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Servier Bio-Innovation LLC

    Enrolling Sites:

    Sylvester
    UMH
    Title:

    A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
    Eligibility Criteria - NCT06478212 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231234 - Shah Ashish

  • Investigator:
    Ashish Shah
    RCname Email

    		Coordinator:

    IRB: 20231234

    		SDG: Neuro Oncology
    Disease Site(s):

    Brain and Nervous System
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    A Biomarker-Guided Phase 2 Study of DB107-RRV (a Retroviral Replicating Vector) Combined with DB107-FC (Flucytosine Extended-Release Tablets) in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma
    Eligibility Criteria - NCT06264388 *This information has been extracted from " www.clinicaltrials.gov"